Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share news the company has completed a bought deal private placement bringing in 15 million dollars. The deal was oversubscribed. Saviuk telling Proactive this capital will allow the company to accelerate the launches of their lead products, Redesca, Enerzair, and Atectura.
Saviuk also told Proactive, the company has announced it has closed the previously announced concurrent $10.0 million private placement with Investissement Québec, which participates in Québec's economic development by stimulating business innovation, entrepreneurship and takeover, as well as investment and export growth.